Intravitreal Bevacizumab for Symptomatic Retinal Arterial Macroaneurysm
I offer the following observations regarding the recent study by Cho and associates. Intravitreal bevacizumab for exudative complications of retinal artery macroaneurysm was first reported in 2009. Since then, there have been several reports indicating benefit from intravitreal bavacizumab for both hemorrhagic and exudative complications of retinal artery macroaneurysm. However, there seems to be little benefit or rationale for such therapy for subfoveal hemorrhage from ruptured retinal artery macroaneurysm. Hemorrhage from retinal artery macroaneurysm, unlike exudation, which is a continuous process that can be demonstrated by leakage on fluorescein angiography, is generally a one-time event that commonly leads to fibrosis (Read more...)